The FDA had previously greenlight the genetically engineered salmon to be sold in the US in 2015, but in 2020 a judge ruled that the agency needed to perform an additional review of the salmon and the chances it could be introduced into the wild and its potential danger to wild salmon populations. As part of that ruling, a judge determined that the FDA did not carry out due diligence when considering the possibility of environmental consequences when it approved the sale of AquAdvantage salmon.